MIRM Mirum Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MIRM

Price (delayed)

$32.07

Market cap

$1.49B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.29

Enterprise value

$1.5B

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, ...

Highlights
The company's gross profit has surged by 178% YoY and by 22% QoQ
The revenue has soared by 177% YoY and by 25% from the previous quarter
The company's debt has surged by 120% YoY
The quick ratio has declined by 25% since the previous quarter and by 19% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://mirumpharma.com
Peers: OMGA

Key stats

What are the main financial stats of MIRM
Market
Shares outstanding
46.61M
Market cap
$1.49B
Enterprise value
$1.5B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.56
Price to sales (P/S)
9.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.36
Earnings
Revenue
$144.73M
EBIT
-$147.38M
EBITDA
-$140.24M
Free cash flow
-$88.95M
Per share
EPS
-$4.29
Free cash flow per share
-$2.16
Book value per share
$7.03
Revenue per share
$3.52
TBVPS
$9.55
Balance sheet
Total assets
$650.64M
Total liabilities
$381.56M
Debt
$307.97M
Equity
$269.08M
Working capital
$313.92M
Liquidity
Debt to equity
1.14
Current ratio
5.2
Quick ratio
4.74
Net debt/EBITDA
-0.04
Margins
EBITDA margin
-96.9%
Gross margin
81.7%
Net margin
-113.4%
Operating margin
-76.5%
Efficiency
Return on assets
-36.9%
Return on equity
-104.1%
Return on invested capital
-52.3%
Return on capital employed
-25.6%
Return on sales
-101.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MIRM stock price

How has the Mirum Pharmaceuticals stock price performed over time
Intraday
1.33%
1 week
0.22%
1 month
17.69%
1 year
71.96%
YTD
64.46%
QTD
1.49%

Financial performance

How have Mirum Pharmaceuticals's revenue and profit performed over time
Revenue
$144.73M
Gross profit
$118.21M
Operating income
-$110.73M
Net income
-$164.19M
Gross margin
81.7%
Net margin
-113.4%
The company's gross profit has surged by 178% YoY and by 22% QoQ
The revenue has soared by 177% YoY and by 25% from the previous quarter
The operating margin has soared by 72% YoY and by 25% from the previous quarter
The company's net margin fell by 42% YoY but it rose by 26% QoQ

Growth

What is Mirum Pharmaceuticals's growth rate over time

Valuation

What is Mirum Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.56
P/S
9.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.36
The EPS has grown by 9% from the previous quarter
Mirum Pharmaceuticals's equity has soared by 59% YoY
MIRM's price to book (P/B) is 36% lower than its last 4 quarters average of 7.1 and 12% lower than its 5-year quarterly average of 5.2
The revenue has soared by 177% YoY and by 25% from the previous quarter
MIRM's price to sales (P/S) is 2.4% higher than its last 4 quarters average of 8.9

Efficiency

How efficient is Mirum Pharmaceuticals business performance
Mirum Pharmaceuticals's return on assets has shrunk by 173% YoY but it has increased by 22% QoQ
The ROS has plunged by 62% YoY but it has grown by 26% from the previous quarter
The ROE has increased by 22% QoQ
The ROIC has grown by 12% from the previous quarter

Dividends

What is MIRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MIRM.

Financial health

How did Mirum Pharmaceuticals financials performed over time
MIRM's total assets is 71% higher than its total liabilities
The total liabilities has soared by 96% YoY and by 4.5% from the previous quarter
MIRM's total assets has soared by 79% YoY and by 47% QoQ
The company's debt is 14% higher than its equity
The company's debt has surged by 120% YoY
The debt to equity has plunged by 71% from the previous quarter but it has grown by 37% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.